NTG 101
Alternative Names: NTG-101Latest Information Update: 22 Mar 2024
At a glance
- Originator Notogen
- Class Anti-inflammatories; Recombinant proteins
- Mechanism of Action Connective tissue growth factor replacements; Transforming growth factor beta1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Intervertebral disc degeneration
Most Recent Events
- 22 Mar 2024 NTG 101 is still in preclinical trials for Intervertebral-disc-degeneration in Canada (Intraspinal, Injection) (Notogen pipeline, March 2024)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Intervertebral-disc-degeneration in Canada (Intraspinal, Injection)
- 20 Nov 2018 Preclinical trials in Intervertebral disc degeneration in Canada (Intraspinal)